International Consensus on drug allergy
- PMID: 24697291
- DOI: 10.1111/all.12350
International Consensus on drug allergy
Abstract
When drug reactions resembling allergy occur, they are called drug hypersensitivity reactions (DHRs) before showing the evidence of either drug-specific antibodies or T cells. DHRs may be allergic or nonallergic in nature, with drug allergies being immunologically mediated DHRs. These reactions are typically unpredictable. They can be life-threatening, may require or prolong hospitalization, and may necessitate changes in subsequent therapy. Both underdiagnosis (due to under-reporting) and overdiagnosis (due to an overuse of the term ‘allergy’) are common. A definitive diagnosis of such reactions is required in order to institute adequate treatment options and proper preventive measures. Misclassification based solely on the DHR history without further testing may affect treatment options, result in adverse consequences, and lead to the use of more-expensive or less-effective drugs, in contrast to patients who had undergone a complete drug allergy workup. Several guidelines and/or consensus documents on general or specific drug class-induced DHRs are available to support the medical decision process. The use of standardized systematic approaches for the diagnosis and management of DHRs carries the potential to improve outcomes and should thus be disseminated and implemented. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), formed by the European Academy of Allergy and Clinical Immunology (EAACI), the American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI), and the World Allergy Organization (WAO), has decided to issue an International CONsensus (ICON) on drug allergy. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences and deficiencies of evidence, thus providing a comprehensive reference document for the diagnosis and management of DHRs.
Similar articles
-
International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem.World Allergy Organ J. 2017 Apr 18;10(1):14. doi: 10.1186/s40413-017-0145-4. eCollection 2017. World Allergy Organ J. 2017. PMID: 28451053 Free PMC article.
-
International consensus on (ICON) pediatric asthma.Allergy. 2012 Aug;67(8):976-97. doi: 10.1111/j.1398-9995.2012.02865.x. Epub 2012 Jun 15. Allergy. 2012. PMID: 22702533 Free PMC article.
-
International Consensus (ICON): allergic reactions to vaccines.World Allergy Organ J. 2016 Sep 16;9(1):32. doi: 10.1186/s40413-016-0120-5. eCollection 2016. World Allergy Organ J. 2016. PMID: 27679682 Free PMC article.
-
Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology.Ann Allergy Asthma Immunol. 1999 Dec;83(6 Pt 3):665-700. Ann Allergy Asthma Immunol. 1999. PMID: 10616910
-
[WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases].Wien Med Wochenschr. 1999;149(14-15):410-4. Wien Med Wochenschr. 1999. PMID: 10584284 Review. German.
Cited by
-
Recent findings on drug hypersensitivity in children.Front Allergy. 2024 Feb 7;5:1330517. doi: 10.3389/falgy.2024.1330517. eCollection 2024. Front Allergy. 2024. PMID: 38384771 Free PMC article. Review.
-
Characterization of immunologically detectable T-cell sensitization, Immunohistochemical detection of pro-inflammatory cytokines, and clinical parameters of patients after allogeneic intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans.BMC Oral Health. 2022 Dec 10;22(1):592. doi: 10.1186/s12903-022-02584-6. BMC Oral Health. 2022. PMID: 36496367 Free PMC article. Clinical Trial.
-
Desensitization for the prevention of drug hypersensitivity reactions.Korean J Intern Med. 2022 Feb;37(2):261-270. doi: 10.3904/kjim.2021.438. Epub 2022 Feb 28. Korean J Intern Med. 2022. PMID: 35123386 Free PMC article. Review.
-
Immediate Hypersensitivity to Fluoroquinolones: A Cohort Assessing Cross-Reactivity.Open Forum Infect Dis. 2022 Mar 2;9(4):ofac106. doi: 10.1093/ofid/ofac106. eCollection 2022 Apr. Open Forum Infect Dis. 2022. PMID: 35355888 Free PMC article.
-
Anaphylaxis in Brazil between 2011 and 2019.Clin Exp Allergy. 2022 Sep;52(9):1071-1078. doi: 10.1111/cea.14193. Epub 2022 Jul 20. Clin Exp Allergy. 2022. PMID: 35856139 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical